Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,218 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ASCEND Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3127760 in Healthy Participants

NCT01968070
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3127760, Celecoxib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

NCT05466422
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MK-2214, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
12
States / cities
Glendale, California • Los Alamitos, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 5:42 AM EDT
Terminated Phase 1 Interventional Results available

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

NCT03306420
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
M4112
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

NCT03230383
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06865571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

NCT00926731
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
AZD1152, LDAC (low dose cytosine arabinoside)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 18, 2026, 5:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

NCT04547361
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2511, E2511 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

NCT05462522
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
RO7303509, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Palo Alto, California • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 18, 2026, 5:42 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

NCT05222802
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ERAS-801
Drug
Lead sponsor
Katmai Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 18, 2026, 5:42 AM EDT
Terminated Phase 1 Interventional

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

NCT03182257
View directory record Official record
Conditions
Solid Tumor
Interventions
ONO-7579
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lake Success, New York • New York, New York • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986365, Rabeprazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

NCT02725957
View directory record Official record
Conditions
Healthy Volunteer Subjects
Interventions
Trehalose for IV Infusion, Saline 0.9% IV
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

NCT03056729
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Volunteer
Interventions
BIIB076, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
8
States / cities
Hallandale, Florida • Orlando, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

NCT01074372
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN727, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 18, 2026, 5:42 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Putative Cognitive Enhancer VU319

NCT04051801
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Dose Escalation of VU319, Dose Escalation of Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

NCT01354158
View directory record Official record
Conditions
Spinal Cord Injury, Hypotension
Interventions
Droxidopa
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

NCT04627532
View directory record Official record
Conditions
Healthy
Interventions
PF-07304814, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

NCT02611921
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

NCT01979406
View directory record Official record
Conditions
Anthrax Infection
Interventions
AVA, Ad4-PA-1, Ad4-PA-GPI-1
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Kansas City, Kansas • Silver Spring, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

NCT04763226
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986308, Placebo (for BMS-986308), Furosemide
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 18, 2026, 5:42 AM EDT
Recruiting Phase 1 Interventional

A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes

NCT07568678
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HMS1005, Matching placebo
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-235 in Healthy Subjects

NCT05246878
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 18, 2026, 5:42 AM EDT
Recruiting No phase listed Observational

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

NCT05002543
View directory record Official record
Conditions
Cardiac Valve Disease
Interventions
Not listed
Lead sponsor
Corcym S.r.l
Industry
Eligibility
Not listed
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
9
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Portland, Maine + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 18, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of MGD010 in Healthy Subjects

NCT02376036
View directory record Official record
Conditions
Healthy Subjects
Interventions
MGD010, Placebo, Hepatitis A vaccine
Drug · Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 18, 2026, 5:42 AM EDT